Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUROSTEM in Alzheimer's Disease
NCT02054208Phase 2Completed
- Sponsor
- MEDIPOST
- Start
- Mar 2014
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) (3 arms), sponsored by MEDIPOST. Primary endpoint: Number of subjects with adverse events at 24 weeks. Started Mar 2014; status: completed.
02
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02054208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054208.